Substance / Medication

Goserelin acetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of prostate

Neoplasm of breast

Endometriosis (clinical)

Malignant tumour of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Prostate specific Ag

LOINC 2857-1

primary

Research Evidence

Published studies and systematic reviews

Sort:

Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas.

Vilos George A, Vilos Angelos G, Abu-Rafea Basim et al. · Fertil Steril · 2006

PMID: 16579996RCT

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.

Shimizu Daisuke, Ishikawa Takashi, Tanabe Mikiko et al. · Breast Cancer · 2014

PMID: 23184499Trial

Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.

Berglund Ryan K, Tangen Catherine M, Powell Isaac J et al. · Urology · 2012

PMID: 22386416TrialFull text (PMC)

[Evaluation of pain reduction upon injecting goserelin acetate using an ice pack].

Ikeda Katsumi, Ogawa Yoshinori, Nagahara Hisashi et al. · Gan To Kagaku Ryoho · 2010

PMID: 20154487Trial

Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.

Muneyyirci-Delale Ozgul, Richard-Davis Gloria, Morris Tom et al. · Clin Ther · 2007

PMID: 17919549Trial

Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate.

Mohamed Kamel Abdelhakim, Davies W A R, Lashen Hany · Fertil Steril · 2006

PMID: 16978621Trial

3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.

Fontana D, Mari M, Martinelli A et al. · Urol Int · 2003

PMID: 12740498Trial

Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Asbury Robert F, Brunetto Virginia L, Lee Roger B et al. · Am J Clin Oncol · 2002

PMID: 12477997Trial

Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up evaluation.

Donnez J, Vilos G, Gannon M J et al. · Fertil Steril · 2001

PMID: 11239552Trial

[Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study].

Calvo Lugo G E, Sauceda González L F, Jiménez Perea M L et al. · Ginecol Obstet Mex · 2000

PMID: 10774095Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Medical Oncology Physician

Internal Medicine — Medical Oncology

Urology

Health Goals

Goals connected through associated conditions

Screen for Cancer Risk

Quick Facts

Type: Substance / Medication
Fully Specified Name: Goserelin acetate (substance)
SNOMED CT: 108773006
UMLS CUI: C0700476

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.